ImmunoEdge
Contact
Unlocking immune targets from minimal tumor samples
ImmunoEdge is developing a technology to uncover clinically relevant tumor peptides from minimally invasive biopsies, enabling actionable immunotherapy target discovery and longitudinal tracking over treatment.
Get In Touch
Supported by
ABOUT IMMUNOEDGE
Designed for clinical reality, ImmunoEdge is being built to uncover immune‑visible tumor peptides from ultra‑low‑input biopsies that standard workflows systematically miss, aiming to enable higher‑confidence and longitudinal immune target discovery for future immunotherapy programs.
THE CHALLENGE
Why traditional methods in immune target discovery don’t work
Current immunopeptidomics workflows can lose up to 99% of tumor immunopeptides from small biopsies, causing many clinically relevant immune targets to go undetected.
01
Loss and bias in affinity-based workflows
Affinity-based methods introduce sample loss and bias, especially with low-input tumor material, causing many immune-relevant peptides to be missed.
02
High sample requirements and single-shot analyses
Many workflows need large tumor samples and only allow single analyses, limiting longitudinal studies and real-world applicability.
03
Genome-based predictions miss low-expression targets
Predictive methods often overlook low-expression but immune-visible peptides, creating blind spots in discovery and therapeutic planning.
OUR SOLUTION
Unlocking precision for immunotherapy programs
Our approach is being built to overcome the limitations of standard workflows, giving researchers and clinicians actionable insights from small, real-world samples.
Learn More
More complete and longitudinal visibility
Capture a broader landscape of tumor immune targets over time, even from minimal biopsy samples, enabling a more accurate and continuous understanding of the immune environment.
Higher-confidence target selection
Prioritize immunotherapy candidates with confidence by relying on comprehensive, unbiased peptide data that reveals clinically relevant targets standard methods miss.
De-risked downstream therapeutic development
Reduce uncertainty in R&D programs by uncovering previously hidden tumor peptides, supporting better-informed decisions and more reliable translational outcomes.
OUR TEAM
Leadership behind ImmunoEdge
Mogjib Salek
PhD — Founder & CSO
Background in Structural Biochemistry and T-cell Signaling (Heidelberg & Oxford). Led platform development enabling neoepitope discovery from patient-derived tumor samples at DKFZ/NCT Heidelberg.
Jalal Vakili
MD, PhD — Executive Advisor
Clinical Oncology and Trial Strategy experience (Jules Bordet/Servier Oncology). Former CEO (Ovizio Imaging Systems & Chromacure SA) with a track record in partnerships, deal-making, and program leadership.
Our Advisory Board
Oreste Acuto, PhD
Pioneer in T-cell Receptor Signaling. Expertise in T-cell biology and immunotherapy translation (University of Oxford, Institut Pasteur, Dana-Farber Cancer Institute)
Christophe Masselon, PhD
Pioneer in Neutral Particle Mass Spectrometry. Expertise in clinical mass spectrometry and peptidomics systems (CEA, ETH Zürich, PNNL)
Daniel Böhi, PhD
Former CEO Capri-Sun. Executive Advisor for strategy, business development, and early-stage funding (Capri-Sun, Nestlé)
Join us in transforming cancer care
We are building collaborations with translational oncology and biotech teams to develop immune target discovery from limited clinical samples. If you’re exploring immunopeptidomics, neoepitope discovery, or longitudinal immune target tracking and are interested in pilot or co‑development opportunities, we’d love to hear from you.
Become a Partner
FAQs
Frequently Asked Questions
Here are answers to some of the most frequently asked questions about ImmunoEdge, our approach.
What does ImmunoEdge do?
How is ImmunoEdge different from standard immunopeptidomics approaches?
What types of samples can ImmunoEdge work with?
How can I collaborate or learn more?
ImmunoEdge
Developing clinical‑grade immune target discovery from ultra‑low‑input samples.
Aiming to enable the next generation of precision immunotherapy.
ImmunoEdge is currently in pre‑commercial development and is not yet offering clinical or commercial services.
Supported by
© 2025 ImmunoEdge. All rights reserved.
Privacy Policy
ImmunoEdge
Contact
Unlocking immune targets from minimal tumor samples
ImmunoEdge is developing a technology to uncover clinically relevant tumor peptides from minimally invasive biopsies, enabling actionable immunotherapy target discovery and longitudinal tracking over treatment.
Get In Touch
Supported by
ABOUT IMMUNOEDGE
Designed for clinical reality, ImmunoEdge is being built to uncover immune‑visible tumor peptides from ultra‑low‑input biopsies that standard workflows systematically miss, aiming to enable higher‑confidence and longitudinal immune target discovery for future immunotherapy programs.
THE CHALLENGE
Why traditional methods in immune target discovery don’t work
Current immunopeptidomics workflows can lose up to 99% of tumor immunopeptides from small biopsies, causing many clinically relevant immune targets to go undetected.
01
Loss and bias in affinity-based workflows
Affinity-based methods introduce sample loss and bias, especially with low-input tumor material, causing many immune-relevant peptides to be missed.
02
High sample requirements and single-shot analyses
Many workflows need large tumor samples and only allow single analyses, limiting longitudinal studies and real-world applicability.
03
Genome-based predictions miss low-expression targets
Predictive methods often overlook low-expression but immune-visible peptides, creating blind spots in discovery and therapeutic planning.
OUR SOLUTION
Unlocking precision for immunotherapy programs
Our approach is being built to overcome the limitations of standard workflows, giving researchers and clinicians actionable insights from small, real-world samples.
Learn More
More complete and longitudinal visibility
Capture a broader landscape of tumor immune targets over time, even from minimal biopsy samples, enabling a more accurate and continuous understanding of the immune environment.
Higher-confidence target selection
Prioritize immunotherapy candidates with confidence by relying on comprehensive, unbiased peptide data that reveals clinically relevant targets standard methods miss.
De-risked downstream therapeutic development
Reduce uncertainty in R&D programs by uncovering previously hidden tumor peptides, supporting better-informed decisions and more reliable translational outcomes.
OUR TEAM
Leadership behind ImmunoEdge
Mogjib Salek
PhD — Founder & CSO
Background in Structural Biochemistry and T-cell Signaling (Heidelberg & Oxford). Led platform development enabling neoepitope discovery from patient-derived tumor samples at DKFZ/NCT Heidelberg.
Jalal Vakili
MD, PhD — Executive Advisor
Clinical Oncology and Trial Strategy experience (Jules Bordet/Servier Oncology). Former CEO (Ovizio Imaging Systems & Chromacure SA) with a track record in partnerships, deal-making, and program leadership.
Our Advisory Board
Oreste Acuto, PhD
Pioneer in T-cell Receptor Signaling. Expertise in T-cell biology and immunotherapy translation (University of Oxford, Institut Pasteur, Dana-Farber Cancer Institute)
Christophe Masselon, PhD
Pioneer in Neutral Particle Mass Spectrometry. Expertise in clinical mass spectrometry and peptidomics systems (CEA, ETH Zürich, PNNL)
Daniel Böhi, PhD
Former CEO Capri-Sun. Executive Advisor for strategy, business development, and early-stage funding (Capri-Sun, Nestlé)
Join us in transforming cancer care
We are building collaborations with translational oncology and biotech teams to develop immune target discovery from limited clinical samples. If you’re exploring immunopeptidomics, neoepitope discovery, or longitudinal immune target tracking and are interested in pilot or co‑development opportunities, we’d love to hear from you.
Become a Partner
FAQs
Frequently Asked Questions
Here are answers to some of the most frequently asked questions about ImmunoEdge, our approach.
What does ImmunoEdge do?
How is ImmunoEdge different from standard immunopeptidomics approaches?
What types of samples can ImmunoEdge work with?
How can I collaborate or learn more?
ImmunoEdge
Developing clinical‑grade immune target discovery from ultra‑low‑input samples.
Aiming to enable the next generation of precision immunotherapy.
ImmunoEdge is currently in pre‑commercial development and is not yet offering clinical or commercial services.
Supported by
© 2025 ImmunoEdge. All rights reserved.
Privacy Policy
Unlocking immune targets from minimal tumor samples
ImmunoEdge is developing a technology to uncover clinically relevant tumor peptides from minimally invasive biopsies, enabling actionable immunotherapy target discovery and longitudinal tracking over treatment.
Get In Touch
Supported by
ABOUT IMMUNOEDGE
Designed for clinical reality, ImmunoEdge is being built to uncover immune‑visible tumor peptides from ultra‑low‑input biopsies that standard workflows systematically miss, aiming to enable higher‑confidence and longitudinal immune target discovery for future immunotherapy programs.
THE CHALLENGE
Why traditional methods in immune target discovery don’t work
Current immunopeptidomics workflows can lose up to 99% of tumor immunopeptides from small biopsies, causing many clinically relevant immune targets to go undetected.
01
Loss and bias in
affinity-based
workflows
Affinity-based methods introduce sample loss and bias, especially with low-input tumor material, causing many immune-relevant peptides to be missed.
02
High sample requirements and single-shot analyses
Many workflows need large tumor samples and only allow single analyses, limiting longitudinal studies and real-world applicability.
03
Genome-based predictions miss low-expression targets
Predictive methods often overlook low-expression but immune-visible peptides, creating blind spots in discovery and therapeutic planning.
OUR SOLUTION
Unlocking precision for immunotherapy programs
Our approach is being built to overcome the limitations of standard workflows, giving researchers and clinicians actionable insights from small, real-world samples.
Learn More
More complete and longitudinal visibility
Capture a broader landscape of tumor immune targets over time, even from minimal biopsy samples, enabling a more accurate and continuous understanding of the immune environment.
Higher-confidence target selection
Prioritize immunotherapy candidates with confidence by relying on comprehensive, unbiased peptide data that reveals clinically relevant targets standard methods miss.
De-risked downstream therapeutic development
Reduce uncertainty in R&D programs by uncovering previously hidden tumor peptides, supporting better-informed decisions and more reliable translational outcomes.
OUR TEAM
Leadership behind ImmunoEdge
Mogjib Salek
PhD — Founder & CSO
Background in Structural Biochemistry and T-cell Signaling (Heidelberg & Oxford). Led platform development enabling neoepitope discovery from patient-derived tumor samples at DKFZ/NCT Heidelberg.
Jalal Vakili
MD, PhD — Executive Advisor
Clinical Oncology and Trial Strategy experience (Jules Bordet/Servier Oncology). Former CEO (Ovizio Imaging Systems & Chromacure SA) with a track record in partnerships, deal-making, and program leadership.
Our Advisory Board
Oreste Acuto, PhD
Pioneer in T-cell Receptor Signaling. Expertise in T-cell biology and immunotherapy translation (University of Oxford, Institut Pasteur, Dana-Farber Cancer Institute)
Christophe Masselon, PhD
Pioneer in Neutral Particle Mass Spectrometry. Expertise in clinical mass spectrometry and peptidomics systems (CEA, ETH Zürich, PNNL)
Daniel Böhi, PhD
Former CEO Capri-Sun. Executive Advisor for strategy, business development, and early-stage funding (Capri-Sun, Nestlé)
Join us in transforming cancer care
We are building collaborations with translational oncology and biotech teams to develop immune target discovery from limited clinical samples. If you’re exploring immunopeptidomics, neoepitope discovery, or longitudinal immune target tracking and are interested in pilot or co‑development opportunities, we’d love to hear from you.
Become a Partner
FAQs
Frequently Asked Questions
Here are answers to some of the most frequently asked questions about ImmunoEdge, our approach.
What does ImmunoEdge do?
How is ImmunoEdge different from standard immunopeptidomics approaches?
What types of samples can ImmunoEdge work with?
How can I collaborate or learn more?
ImmunoEdge
Developing clinical‑grade immune target discovery from ultra‑low‑input samples.
Aiming to enable the next generation of precision immunotherapy.
ImmunoEdge is currently in pre‑commercial development and is not yet offering clinical or commercial services.
Supported by
© 2025 ImmunoEdge. All rights reserved.
Privacy Policy